CD274 and urothelial carcinoma: The KEYNOTE-045 and KEYNOTE-052 studies demonstrated the superiority of pembrolizumab over chemotherapy in terms of longer overall survival and lower rates of treatment-related adverse events in advanced urothelial carcinoma (UC) patients with PD-L1 combined positive score (CPS) ≥ 10% as first- and second-line therapies (2, 3).